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Abstract
A total of 176 genes homozygously deleted in human lung cancer were identified by DNA array-
based whole genome scanning of 52 lung cancer cell lines and subsequent genomic PCR in 74 cell
lines, including the 52 cell lines scanned. One or more exons of these genes were homozygously
deleted in one (1%) to 20 (27%) cell lines. These genes included known tumor suppressor genes,
e.g., CDKN2A/p16, RB1, and SMAD4, and candidate tumor suppressor genes whose hemizygous
or homozygous deletions were reported in several types of human cancers, such as FHIT, KEAP1,
and LRP1B/LRP-DIP. CDKN2A/p16 and p14ARF located in 9p21 were most frequently deleted
(20/74, 27%). The PTPRD gene was most frequently deleted (8/74, 11%) among genes mapping
to regions other than 9p21. Somatic mutations, including a nonsense mutation, of the PTPRD gene
were detected in 8/74 (11%) of cell lines and 4/95 (4%) of surgical specimens of lung cancer.
Reduced PTPRD expression was observed in the majority (>80%) of cell lines and surgical
specimens of lung cancer. Therefore, PTPRD is a candidate tumor suppressor gene in lung cancer.
Microarray-based expression profiling of 19 lung cancer cell lines also indicated that some of the
176 genes, such as KANK and ADAMTS1, are preferentially inactivated by epigenetic alterations.
Genetic/epigenetic as well as functional studies of these 176 genes will increase our understanding
of molecular mechanisms behind lung carcinogenesis.
INTRODUCTION
Lung cancer is the leading cause of cancer-related deaths in the world (Herbst et al., 2008).
The majority of lung cancers are comprised of four major histological types, which are small
cell lung carcinoma (SCLC) and three nonsmall cell lung carcinoma (NSCLC) types;
adenocarcinoma (ADC), squamous cell carcinoma (SQC), and large cell carcinoma (LCC).
Lung cancer develops through the acquisition of alterations in oncogenes, such as EGFR
(10–40% of ADC) and KRAS (10–30% of ADC), and tumor suppressor genes, such as TP53
(~90% of SCLC; 50% of NSCLC), RB1 (~90% of SCLC; ~20% of NSCLC), CDKN2A/p16
(~50% of NSCLC), and LKB1/STK11 (20–30% of NSCLC) (Minna et al., 2002; Herbst et
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al., 2008). The EGFR, KRAS, and TP53 genes have been subjected to diagnostic and
therapeutic applications (Toloza et al., 2006; Herbst et al., 2008); therefore, identification of
more genes involved in lung carcinogenesis will be highly applicable to further improve the
diagnosis and therapy of lung cancer. Allelic imbalance (AI) studies on lung cancer have
identified several chromosome arms frequently hemizygously deleted, such as 1p, 4q, 5q,
6q, 8p, 11q, 12q, 13q, 17q, and 21q (Shiseki et al., 1996; Kawanishi et al., 1997; Virmani et
al., 1998; Girard et al., 2000). Our recent comparative genome-wide AI study of noninvasive
and invasive lung adenocarcinomas (ADCs) further suggested that AI on each chromosome
arm has different roles in the development and progression of lung cancer (Nakanishi et al.,
2009). Therefore, chromosomal deletions and inactivation of corresponding tumor
suppressor genes are thought to play multiple roles in the development and/or progression of
lung cancer. However, responsible tumor suppressor genes for most of these chromosomal
deletions have not yet been identified.
Homozygous deletion (i.e., deletion of both alleles) is a genetic event causing inactivation of
tumor suppressor genes (Minna et al., 2002; Yokota and Kohno, 2004), and has played an
important role as a tool in identifying several tumor suppressor genes, such as CDKN2A/
p16, PTEN, and SMAD4 (Kamb et al., 1994; Nobori et al., 1994; Hahn et al., 1996; Li et al.,
1997; Steck et al., 1997). Up to the present, DNA array analyses have been performed by
several groups, including ours, to find homozygously deleted regions in lung cancer
genomes (Sato et al., 2005; Tonon et al., 2005; Zhao et al., 2005; Garnis et al., 2006; Imoto
et al., 2006; Nagayama et al., 2007; Weir et al., 2007), and tens of genomic regions with
homozygous deletions have been identified. However, only a few genes located in some of
the homozygously deleted regions were focused on and investigated.
In this study, genes whose exons were removed by homozygous deletions were
comprehensively searched for by a DNA array-based whole genome scanning of 52 human
lung cancer cell lines followed by genomic PCR analyses. Notably, several well-known
tumor suppressor genes, such as RB1, DCC, and BRCA2, have been identified from a single
or a few cases of homozygous deletions detected in a large number of cancer cases analyzed
(Dryja et al., 1986; Fearon et al., 1990; Wooster et al., 1995). The results indicated the
significance of homozygous deletions irrespective of their frequencies for the identification
of novel tumor suppressor genes. Therefore, in the present study, all genes deduced to be
mapped in homozygously deleted regions were examined, even if the deletions were
detected only in a single lung cancer case. Lung cancer cell lines were used for two reasons:
First, the presence of a homozygous deletion can be easily validated by genomic PCR due to
the lack of noncancerous cell contamination that hampers detection of homozygous
deletions; second, frequencies of copy number changes in the genome were shown to be
similar in cell lines and surgical specimens in our previous study (Ogiwara et al., 2008).
Hence homozygous deletions detected in cell lines can be considered to have occurred
mostly in vivo, and not during their establishment and cultivation in vitro. In total, 176
genes located in 45 genomic loci on 17 chromosomes were identified as genes whose exons
were homozygously deleted (Supporting Information Table 1). One of the 176 genes,
PTPRD, was subjected to mutation and expression analyses in surgical specimens of lung
cancer as well as lung cancer cell lines to address the authenticity of this gene as a lung
tumor suppressor gene.
MATERIALS AND METHODS
Human Lung Cancer Cell Lines and Surgical Specimens for Lung Cancer
Forty-three lung cancer cell lines were previously subjected to a SNP array analysis at a
100-kb resolution using an Affymetrics Mapping 100-k array (Affymetrix, Inc., Santa Clara,
California), and they were 11 SCLCs, 21 ADCs, 7 SQCs, and 4 LCCs (Nagayama et al.,
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2007). In the present study, 27 ADC cell lines consisting of 18 lines (II-18, A549, Ma17,
Ma24, H23, H322, H1395, H1437, H2009, H2087, H2122, H2347, PC3, PC7, PC9, PC14,
RERF-LCMS, and VMRC-LCD) analyzed in the previous analysis (Nagayama et al., 2007)
and 9 cell lines (ABC1, Ma10, Ma12, Ma26, Ma29, HCC44, HCC78, HCC193, and
HCC515) prepared for this study were subjected to an array-CGH analysis at a 30-kb
resolution using a Human CGH 185-k array (Agilent Technologies, Santa Clara, California).
Therefore, 52 cell lines in total were scanned for homozygous deletions by using one or two
DNA-array methods at 30 and 100-kb resolutions. To validate homozygous deletion, 74 cell
lines consisting of 52 cell lines subjected to these array analyses and an additional 22 lung
cancer cell lines consisting of 11 SCLCs (H526, H774, H1339, H1450, H1607, H1819, NCI-
H1963, H2195, HCC33, Lu24, and Ms18), 3 ADCs (H2126, H1703, and RERF-LCOK), 3
SQCs (HCC95, Sq-5, and PC10), 3 LCCs (Lu99, Ma2, and Ma25), and 2 adenosquamous
carcinomas (ASCs) (H596 and HCC366) were analyzed. Details of H- and HCC-series cell
lines have been described elsewhere (Burbee et al., 2001). PC-, Lu-, Ma-series, and II-18
cell lines were provided by Drs. Y. Hayata (Tokyo Medical University, Tokyo, Japan), T.
Terasaki (Kanagawa Institute of Technology, Kanagawa, Japan) and S. Hirohashi (National
Cancer Center Research Institute, Tokyo, Japan), M. Takada (National Hospital
Organization Kinki-chuo Chest Medical Center, Osaka, Japan), and K. Hagiwara (Saitama
Medical University, Saitama, Japan), respectively. Cell lines were also obtained from the
American Type Culture Collection (Manassas, Virginia), the Japanese Collection of
Research Bioresources (Tokyo, Japan), and the RIKEN BioResource Center (Tsukuba,
Japan). Genomic DNA and poly A RNA were extracted by standard protocols.
Macro-dissected and micro-dissected cancerous and noncancerous lung cells were obtained
from patients who were treated at the National Cancer Center Hospital, Tokyo, Japan.
Details of these materials were described previously (Matsumoto et al., 2006; Nakamura et
al., 2006). Genomic DNA and total RNA were extracted by standard protocols. This study
was performed under the approval of the Institutional Review Board of National Cancer
Center.
Detection of Homozygous Deletions by Array CGH Analysis
Copy number changes in genomic DNAs of 27 lung cancer cell lines were assessed using a
Human CGH 185-k array covering 181,988 loci and Agilent CGH Analytics Software
(Version 3.3) (Agilent Technologies). Genomic DNAs from these cell lines and 10
lymphoblastoid cell lines were analyzed according to the manufacturer’s protocol using a
human normal genomic DNA mix (Promega) as a reference. First, data for probes that were
located in copy number variable regions deposited in the UCSC genome database and those
that showed log2 ratios < −2.5 or >2.5 in 10 lymphoblastoid cell line DNAs in the present
analyses were removed to mask copy number variable regions. Next, the copy number along
the genome of 27 lung cancer cell lines was inferred by the Aberration Detection Method 2
(ADM2) algorithm. Autosomal regions encompassed by ≥2 consecutive probes with log2
ratios < −2.5 were defined as candidates for homozygously deleted regions. As the probes
were placed at a mean interval of 15-kb, the present homozygous deletion search was
undertaken at a 30-kb resolution.
Validation of Homozygous Deletions
One or more set(s) of PCR primers was designed to amplify genomic fragments that
encompass an exon of genes deduced to be located in homozygously deleted regions by
referring to the information in the UCSC database (http://genome.ucsc.edu/) and was
subjected to multiplex PCR using the IRF1 locus as a reference (Kishimoto et al., 2005). At
least one exon was examined for each gene. Primer sequences are listed in Supporting
Information Table 2. PCR products were separated by electrophoresis on 3% agarose gel
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and visualized by staining with ethidium bromide. When no PCR product was detected, such
an exon was judged as being homozygously deleted.
Expression Analysis of the 176 Genes Homozygously Deleted in Lung Cancer
Information on the expression levels for 23,583 genes of 15 lung cancer cell lines (A549,
H157, H322, H1299, H1437, H1648, H2009, H2122, H2126, H2347, HCC95, HCC193,
HCC366, and HCC515) was previously obtained by analysis using Affymetrix Gene Chips
HG-U133A and HG-U133B (Zhou et al., 2006). Information on those of four other lung
cancer cell lines (H223, H209, H841, and H2141) and cultured noncancerous lung epithelial
cells (Ramirez et al., 2004) was obtained for the present study. Expression data for 160 of
the 176 genes homozygously deleted in lung cancer cell lines were available, and these 160
genes were assessed by 281 probes (Supporting Information Table 1). Differences in
expression levels between lung cancer cell lines and noncancerous lung epithelial cells were
examined by t test, and probes with P < 0.05 were judged as significantly different. In
addition, probes with P < 0.00018 were judged as significantly different after Bonferroni
correction for multiple tests (i.e., 0.05/281 = 0.00018).
Mutation Analysis of the PTPRD Gene
All coding exons of the PTPRD gene were amplified from 10 ng of DNA from 74 cell lines
and 95 surgical specimens of lung cancer by PCR using 44 sets of primers. PCR products
from the cell lines were directly sequenced using a Big Dye Terminator Sequencing kit and
an ABI Prism 3700 Genetic Analyzer (Applied Biosystems, Foster City, California, USA).
PCR products from the surgical specimens were subjected to WAVE analysis according to
the manufacturer’s protocol (Transgenomic, Omaha, Nebraska, USA). PCR products with
different mobilities in the WAVE analysis were purified and directly sequenced.
Quantitative Real-time Reverse Transcription PCR (QRT-PCR) Analysis
Expression levels of the PTPRD gene were evaluated by QRT-PCR using ABI Prism
7900HT (Applied Biosystems). A Taqman probe (5′-
AGGATCAATATCAGTTTTCCTA-3′) and a set of primers (5′-
TGTTAAGAACACAACGAC CAGCTAT-3′ and 5′- TCAAAGCTGCCCAGG
TACTCTAGT-3′) were used as previously described (Sato et al., 2005). PCR was
performed in a single tube in duplicate. Results were expressed as the average of these two
independent tests.
RESULTS AND DISCUSSION
Identification of Genes Homozygously Deleted in 52 Human Lung Cancer Cell Lines
Homozygously deleted regions in 43 lung cancer cell lines were previously searched for at a
100-kb resolution by a SNP array analysis, and 113 genes were deduced to map to
homozygously deleted regions in one or more cell lines (Nagayama et al., 2007). These 113
genes consisted of three genes, CDKN2A/p16, p14ARF (a gene sharing the same exons with
CDKN2A/p16 but encoding a different protein) (Stone et al., 1995) and CDKN2B/p15,
which are considered target tumor suppressor genes for homozygous deletions at
chromosome band 9p21 (Hamada et al., 2000), and 110 genes located in regions other than
9p21 (Fig. 1).
In this study, homozygous deletions were further searched for by an array CGH analysis at a
30-kb resolution in 27 lung cancer cell lines consisting of 18 cell lines previously analyzed
(Nagayama et al., 2007) and 9 cell lines newly prepared (Fig. 1). Among 113 genes found to
be deleted in the previous study (Nagayama et al., 2007), 111 were verified in this study.
Two genes, THSD4 and C20orf133, considered to be homozygously deleted in the previous
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study, were not found to be deleted here. Therefore, these two genes were excluded from
further analyses. In addition, 83 genes not indicated in the previous study were deduced to
be homozygously deleted in the present 30-kb resolution analysis. These 83 genes consisted
of 37 genes in the 9p21 region and 46 genes in other regions. Thus, in total, 194 genes (111
+ 83) were considered to be homozygously deleted in 52 lung cancer cell lines by using two
different DNA array analyses.
To confirm the homozygous deletions of these 194 genes, genomic PCR against DNA
fragments encompassing an exon located in a homozygously deleted region was performed
for all of the 194 genes (primer information in Supporting Information Table 2). One
hundred seventy-six (91%) of the 194 genes showed homozygous deletions of at least one
exon (Fig. 1). These 176 genes included CDKN2A/p16 and CDKN2B/p15, and the results for
deletions of these two genes determined by genomic PCR were consistent with the results
determined by Southern blot analysis in our previous study (Okamoto et al., 1995). On the
other hand, homozygous deletions of exons were not detected in the remaining 18 genes,
probably due to the fact that only intronic or intergenic sequences were deleted or the
deletions deduced were spurious ones caused by experimental errors. Therefore, these 18
genes were excluded from the remaining part of this study. Homozygous deletion of one or
more genes was detected in 20 (74%) of the 27 cell lines analyzed by the present array CGH
analysis, but not in the remaining seven cell lines. Among a total of 52 cell lines subjected to
the present and/or previous homozygous deletion scanning, homozygous deletion of one or
more genes was detected in 36 (69%) cell lines.
Characteristics and Genomic Status of 176 Genes Homozygously Deleted in Lung Cancer
Cell Lines
The 176 genes with verified homozygous deletions are listed in Table 1 and Supporting
Information Table 1. They consisted of 171 protein-encoding genes and five miRNA genes
(genes 58, 78, 167–169). These 176 genes were located in 45 regions on 17 chromosomes
(Supporting Information Fig. 1). They included known tumor suppressor genes, CDKN2A/
p16, p14ARF, CDKN2B/p15, RB1, and SMAD4 (genes 80–82, 131, and 155 in Table 1)
(Futreal et al., 2004), as well as candidate tumor suppressor genes shown to be
hemizygously or homozygously deleted in several types of human cancers, such as LRP1B/
LRP-DIP, FHIT, PTPRD and KEAP1 (genes 3, 18, 47, and 157 in Table 1) (Sozzi et al.,
1996;Liu et al., 2000;Sonoda et al., 2004;Sato et al., 2005;Singh et al., 2006;Stallings et al.,
2006;Ohta et al., 2008).
Frequencies of homozygous deletion for these 176 genes were examined in 74 lung cancer
cell lines, consisting of 52 cell lines used for the array analyses and 22 additional cell lines,
by genomic PCR using the same sets of primers as described above (Supporting Information
Table 2). One to 75 of these genes were homozygously deleted in 44 of the 74 cell lines
analyzed. No gene was deleted in the remaining 30 cell lines (Supporting Information Table
1). Homozygous deletion of each gene was detected in one (1%) to 20 (27%) of the 74 cell
lines. Sixty-four (36%) of the 176 genes were deleted in two or more cell lines (Supporting
Information Table 3), while the other 112 (64%) were deleted in a single cell line. The
CDKN2A/p16 and p14ARF genes (genes 80–81) in the 9p21 region were most frequently
deleted (20/74, 27%). Thirty-four genes deleted in two or more cell lines were located in
regions other than 9p21 (Table 2). A candidate tumor suppressor gene, PTPRD (gene 47),
was most frequently deleted (8/74, 11%) among them. Other known candidate tumor
suppressors, LRP1B (gene 3), FHIT (gene 18), and KEAP1 (gene 157), were also included in
these 34 genes. Therefore, other genes listed in Table 2 will be also strong candidates for
lung tumor suppressors.
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Expression Status of the 176 Genes Homozygously Deleted in Lung Cancer Cell Lines
Nineteen of the 44 cell lines with homozygous deletion were available for information on
expression levels of 23,583 genes obtained by microarray analysis. These cell lines included
all four major histological types of lung cancers. Information on expression levels was
available for 160 (91%) of the 176 genes. Most of these genes showed nonsignificant signals
(i.e., absent call) in cell lines with homozygous deletion of the corresponding genes, and
such genes were LRP1B (gene 3), PTPRD (gene 47), CDKN2A/p16, and p14ARF (genes 80–
81 assessed by the same probes), CDKN2B (gene 82), RB1 (gene 131) and KEAP1 (gene
157) (Table 1). On the other hand, some genes with deletions of parts of genes, such as
FHIT (gene 18), showed significant signals (i.e., present call) in cell lines with homozygous
deletions. As for the FHIT gene, transcripts lacking exons, which are homozygously deleted,
were previously shown to be expressed in lung cancer cells (Sozzi et al., 1996).
Expression data on eight cultured noncancerous lung epithelial cells were also available for
the same set of genes as in lung cancer cell lines (Zhou et al., 2006). Therefore, we searched
for genes whose expression was significantly lower in lung cancer cells compared to
noncancerous lung epithelial cells. In 55 (31%) genes, at least one probe showed a level of
expression significantly lower than that in noncancerous lung epithelial cells (T/N ratio <1
and P < 0.05 by t test, marked in blue in Table 1 and Supporting Information Table 1).
Expression levels in 52 (95%) of these 55 genes remained significantly lower after removing
lung cancer cases with homozygous deletion. The differences in expression of 18 genes
(10%) remained significant after Bonferroni correction for multiple tests (i.e., P < 0.00018,
marked in red in Table 1 and Supporting Information Table 1), and that of 13 (72%) genes
remained significant after removing cases with homozygous deletion. These genes included
the KANK and ADAMTS1 (genes 131 and 175) candidate tumor suppressor genes whose
down-regulation by epigenetic alterations rather than genetic alterations in renal and lung
cancers, respectively, were reported (Sarkar et al., 2002; Choi et al., 2008). It was noted that
homozygous deletions of these three genes were detected only in one cell line, respectively.
The results suggest that the present 176 genes include genes preferentially inactivated in
lung cancer cells by epigenetic alterations rather than homozygous deletions.
PTPRD Alterations in Human Lung Cancer
Homozygous deletions and mutations in the PTPRD gene in human lung cancer and other
cancers, as well as the ability of PTPRD protein to inhibit growth and to cause apoptosis
have indicated that PTPRD is a tumor suppressor gene (Sjoblom et al., 2006; Weir et al.,
2007; Ding et al., 2008; Solomon et al., 2008; Veeriah et al., 2009). Thus, we searched for
mutations in the PTPRD gene in both cell lines and surgical specimens of lung cancer.
Sequencing of all coding exons in 74 lung cancer cell lines revealed that eight cell lines
(11%) had nonsynonymous (i.e., associated with amino acid change) nucleotide
substitutions that were not deposited in the dbSNP database (Table 3). The substitution in
H2171 cells was validated to be a somatic mutation, by the absence of this substitution in the
corresponding lymphoblastoid cell line (Supporting Information Fig. 2A). The other seven
substitutions detected in the remaining seven cell lines were also likely to be somatic
mutations because these substitutions were not detected in noncancerous cells of 95 different
individuals (see below), and each of them was detected in only one of the 74 lung cancer
cell lines and in none of the 95 primary tumors. Among the 95 surgical specimens analyzed
for PTPRD mutations, four cases (4%) were concluded as having somatic mutations because
nucleotide substitutions were detected only in cancer cells and not in the corresponding
noncancerous cells (Table 3). One was a nonsense mutation, two were missense mutations,
and the remaining one was a mutation in an intronic sequence. By RT-PCR and sequencing,
mutant alleles were shown to be expressed in all of the eight cell lines with PTPRD
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mutations and a surgical specimen whose RNA was available for analysis (Supporting
Information Fig. 2A).
The PTPRD mutations detected in this study were dispersed through the PTPRD protein as
previously observed in lung and others cancers (Fig. 2A) (Sjoblom et al., 2006;Weir et al.,
2007;Solomon et al., 2008;Veeriah et al., 2009). It was noted that the same mutations were
not present among the mutations detected in human cancers up to the present, and hot spots
for mutations were not obvious (Supporting Information Fig. 2B and 2C). A recent study
indicated that several mutant PTPRD proteins have lower abilities than the wild-type protein
to inhibit growth and to cause apoptosis in cells (Solomon et al., 2008). In addition, a subset
of mutations, including Gly79X detected in the present study, were nonsense mutations
causing a production of truncated PTPRD proteins lacking the whole or a part of protein
tyrosine phosphatase catalytic domains. These results indicate that somatic PTPRD
mutations are a genetic event causing functional inactivation of the PTPRD gene in human
cancer cells.
We next examined the expression of the PTPRD gene in both cell lines and surgical
specimens of lung cancer. We previously reported that the majority (>90%) of lung cancer
cell lines, including eight cell lines with homozygous PTPRD deletions showed lower
expression levels than noncancerous lung cells (Sato et al., 2005). In this study, eight cell
lines with PTPRD mutations were also shown to express lower levels compared to normal
lung tissue (Table 3). Sixty surgical specimens of lung tumors were also subjected to QRT-
PCR expression analysis. Fifty-one (85%) specimens showed lower levels of PTPRD
expression than the mean-2SD for seven noncancerous lung tissues, therefore, these samples
were judged as having a reduced PTPRD expression (Fig. 2B). Two specimens with PTPRD
mutations for which RNA was available also showed reduced PTPRD expression (Table 3).
Differences in PTPRD levels between noncancerous lung tissues and all lung cancers, ADCs
or SQCs were significant (P < 0.05 by t test). Two LCCs also showed reduced PTPRD
expression. A SCC case examined also showed a lower level of PTPRD, however, was not
judged as having a reduced PTPRD expression according to the criteria above.
We also examined PTPRD expression in non-cancerous lung component cells and cancerous
cells which were obtained by micro-dissection of surgical specimens (Nakamura et al.,
2006). PTPRD expression was detected in noncancerous lung component cells with the
highest expression in type II alveolar epithelial cells, candidate precursor cells for lung ADC
(Otto, 2002) (Fig. 2C). The levels of expression in five lung cancer samples were lower than
those of any component cells (cases 2, 3, 4, 7, and 10 in Fig. 2C). These results suggested
that reduced PTPRD expression commonly occurs in lung carcinogenesis. Recently, reduced
expression of PTPRD was shown to be a frequent event in human glioblastoma, and to be
caused by hypermethylation of the promoter region of the PTPRD gene (Veeriah et al.,
2009). Therefore, it was strongly suggested that PTPRD is silenced by a promoter
hypermethylation also in lung cancer, although methylation status of the PTPRD gene was
not examined in this study.
CONCLUSION
We identified 176 genes homozygously deleted in human lung cancer. These genes included
known tumor suppressor genes and candidate tumor suppressor genes, whose hemizygous or
homozygous deletions as well as intragenic mutations had been reported in several types of
human cancers. Furthermore, these 176 genes include genes preferentially inactivated by
epigenetic alterations, such as KANK and ADAMTS1. Indeed, one of these candidates,
PTPRD, was shown to be genetically and/or epigenetically altered in a considerable fraction
of lung cancer. Therefore, this set of genes will be informative to identify novel lung tumor
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suppressor genes. The Gene Set Enrichment Analysis (GSEA) (Subramanian et al., 2005)
suggests that genes with specific functions or involved in specific signaling pathways are not
significantly enriched among these 176 genes. Thus, it was suggested that genes involved in
a variety of biological processes could function as lung tumor suppressors. Further genetic/
epigenetic as well as functional studies of these 176 genes will help understanding of
molecular mechanism of lung carcinogenesis. In fact, the present homozygous deletion
scanning was performed on a set of 52 lung cancer cell lines including all four major
histological types of lung cancer. However, fractions of ADC (30/52, 58%) and SQC (7/52,
13%) were larger and smaller than those in the population of lung cancer patients (Parkin et
al., 2004), respectively, therefore, scanning of other sets of lung cancer that are predominant
for SQC might provide additional genes.
One to 75 genes were homozygously deleted in 44 lung cancer cell lines analyzed, while no
genes was deleted in the remaining 30 cell lines. The result might imply that the intrinsic
genomic stability against homozygous deletion is different among lung cancer cases. We
recently reported genetic/epigenetic alteration profiles of known oncogenes and tumor
suppressor genes in the cell lines used in this study (Medina et al., 2008; Blanco et al.,
2009). Therefore, relationships between these alterations and homozygous deletions of those
176 genes were examined. Interestingly, numbers of genes with homozygous deletions are
significantly or marginally significantly different according to alterations of tumor
suppressor genes, TP53, CDKN2A/p16, LKB1, and PTEN (Supporting Information Table 4).
Multivariate analysis indicated that only the CDKN2A/p16 alteration among them was
independently associated with the number of genes homozygously deleted. The result
suggests that CDKN2A/p16 alteration is involved in genomic instability inducing
homozygous deletions as this gene is critical for the maintenance of genome integrity in
human cells (McDermott et al., 2006). Interestingly, the cell lines with homozygous
CDKN2A/p16 deletions carried deletions of significantly larger number of genes than those
with promoter hypermethylation and mutation of the CDKN2A/p16 gene; and those without
(Supporting Information Fig. 3). Therefore, homozygous CDKN2A/p16 deletion can be a
marker of intrinsic instability for homozygous deletion. More detailed analysis of genetic/
epigenetic interactions as well as functional interactions among genes altered in lung cancer
cells will further provide insights into the molecular mechanism of lung carcinogenesis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Strategy to identify genes homozygously deleted in lung cancer. A previous search on 43
lung cancer cell lines led to the identification of 113 genes deduced to be homozygously
deleted (Nagayama et al., 2007). The present search on 27 lung cancer cell lines (18 cell
lines overlaped) led to the identification of an additional 83 genes, and excluded two genes
from the 113 genes above. Genomic PCR for exons of 194 genes led to the validation of
homozygous deletions in 176 genes.
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PTPRD mutation and expression in lung cancer. (A) Location of missense and nonsense
mutations detected in the present and previous studies. Ig, immunoglobulin-like C2-type
domain; FN3, fibronectin type III domain; TM, transmembrane domain; PTPc, protein
tyrosine phosphatase catalytic domain. (B) Expression in macro-dissected cancerous and
noncancerous lung cells. Values for four paired noncancerous and cancerous lung tissues are
connected. Expression levels are indicated after adjusting the mean for the levels of
expression in seven cases of noncancerous lung tissues to 1. Mean values are indicated by
horizontal bars if the group has three or more samples. The threshold level to judge as
reduced expression is indicated by a dashed line. (C) Expression in micro-dissected
cancerous and noncancerous lung cells. The levels of PTPRD expression relative to those of
GAPDH expression are shown after adjusting the level of PTPRD expression in type II
alveolar epithelial cells to 1.
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TABLE 1
Homozygous Deletion and Expression of 17 Genes in Cancerous and Noncancerous Cultured Lung Cells
(Extracted from Supplementary Table 1)
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TABLE 2
34 Genes Mapped to Regions Other Than 9p21 and Homozygously Deleted in Two or More Lung Cancer Cell
Lines
Chromosomal





9p23 PTPRD Protein tyrosine phosphatase, receptor type D 8 (11)
2q21 LRP1B /LRP-DIP Low density lipoprotein-related protein 1B 7 (9)
3p14 FHIT Dinucleosidetriphosphatase 4 (5)
2q24 GRB14 Growth factor receptor-bound protein 14 2 (3)
2q24 COBLL1 COBL-like 1 2 (3)
2q24 SLC38A11 Solute carrier family 38, member 11 2 (3)
2q24 SCN3A Sodium channel type III, alpha subunit 2 (3)
2q24 SCN2A Sodium channel type II, alpha subunit 2 (3)
2q24 FAM130A2 TGF-beta induced apoptosis protein 2 2 (3)
2q24 GALNT3 UDP-N-acetyl-alpha-D-galactosamine 2 (3)
5q11 PDE4D Phosphodiesterase 4D 2 (3)
5q31 CTNNA1 Alpha-catennin 2 (3)
7q35 CNTNAP2 Contactin associated protein-like 2 2 (3)
10p11 PARD3 Par-3 partitioning defective 3 homolog 2 (3)
18q21 ME2 Malate dehydrogenase 2 2 (3)
18q21 ELAC1 elaC homolog 1 2 (3)
19p13 KEAP1 Cytosolic inhibitor of Nrf2 2 (3)
19q13 MZF1 Myeloid zinc finger 1 2 (3)
19q13 MGC2752 Hypothetical LOC65996 2 (3)
21q11 LIPI Membrane-associated phospholipase A1 beta 2 (3)
21q11 RBM11 RNA binding motif protein 11 2 (3)
21q11 STCH Stress 70 protein chaperone 2 (3)
21q11 SAMSN1 SAM domain, SH3 domain and nuclear localization signals 1 2 (3)
21q11 NRIP1 Nuclear receptor interacting protein 1 2 (3)
21q11 USP25 Ubiquitin specific peptidase 25 2 (3)
21q11 C21orf34 Chromosome 21 open reading frame 34 2 (3)
21q11 hsa-mir-99a miRNA 2 (3)
21q11 hsa-let-7c miRNA 2 (3)
21q11 hsa-mir-125b-2 miRNA 2 (3)
21q11 CXADR Coxsackie virus and adenovirus receptor 2 (3)
21q11 BTG3/ANA BTG/Tob family protein 2 (3)
21q11 C21orf91 Chromosome 21 open reading frame 91 2 (3)
21q11 CHODL Transmembrane protein MT75 2 (3)
21q11 PRSS7 Enterokinase 2 (3)
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